Patient centric views. V01
Research type
Research Study
Full title
Patient centric views of acceptability of automated diagnostics and prognostication in histopathology
IRAS ID
282568
Contact name
Nicolas Orsi
Contact email
Sponsor organisation
University of Leeds
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 7 months, 16 days
Research summary
When a biopsy or surgical specimen is collected, it is sent to the Histopathology department. These samples are processed and thinly sliced before being placed on a glass slide. They are then reviewed by a specialised doctor called a histopathologist in order to obtain a diagnosis. Traditionally, histopathologists have done this by looking at these glass slides under a microscope and identifying specific cellular features that indicate the presence of cancer. As technology has developed over the years, it is now possible to scan these slides to create an image that a histopathologist can look at on a computer instead. This can make the process faster and also makes it easier to get a second opinion. The corollary of the increased clinical adoption of digital pathology is the creation of large image repositories that can be used for developing artificial intelligence-based diagnostic tools. In this respect, computer algorithms can be developed to help histopathologists in making their diagnoses. Although this technology is still very new and not currently used clinically, there have been many studies carried out to determine the acceptability of this technology to histopathologists. By contrast, we have very little understanding of patients’ views and possible concerns about using such diagnostic tools. This study aims to address this issue by asking patients for their views and opinions on this subject through a qualitative semi-structured interview in the format of a validate questionnaire (using breast cancer as a model cancer).
REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
22/WM/0071
Date of REC Opinion
17 Mar 2022
REC opinion
Further Information Favourable Opinion